{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T20:12:49Z","timestamp":1788120769157,"version":"build-2803163510"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006636","name":"Forskningsr\u00e5det om H\u00e4lsa, Arbetsliv och V\u00e4lf\u00e4rd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006636","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jiac.2024.09.005","type":"journal-article","created":{"date-parts":[[2024,9,7]],"date-time":"2024-09-07T21:44:57Z","timestamp":1725745497000},"page":"102516","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative prospective cohort study of efficacy and safety according to dosage and administration of ceftriaxone for community-acquired pneumonia"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8164-6880","authenticated-orcid":false,"given":"Yosuke","family":"Nakanishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9922-3518","authenticated-orcid":false,"given":"Hiromasa","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7511-3024","authenticated-orcid":false,"given":"Masanori","family":"Kawataki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9628-9125","authenticated-orcid":false,"given":"Tadashi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.09.005_bib1","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1164\/rccm.201908-1581ST","article-title":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases society of America","volume":"200","author":"Metlay","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"7 Suppl","key":"10.1016\/j.jiac.2024.09.005_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jiac.2015.12.019","volume":"22","author":"Mikasa","year":"2016","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.09.005_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12890-017-0424-4","article-title":"Prognostic factors in hospitalized community-acquired pneumonia: a retrospective study of prospective observational cohort","volume":"17","author":"Ito","year":"2017","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jiac.2024.09.005_bib12","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1001\/archinte.164.5.502","article-title":"Causes and factors associated with early failure in hospitalized patients with community-acquired pneumonia","volume":"164","author":"Ros\u00f3nB Carrat\u00e1","year":"2004","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.jiac.2024.09.005_bib4","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/thx.2003.017756","article-title":"Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome","volume":"59","author":"Men\u00e9ndez","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.jiac.2024.09.005_bib5","series-title":"The committee for the Japanese respiratory society in the management of pneumonia in adults guidelines 2017. The JRS guidelines for the management of pneumonia in adults","year":"2017"},{"issue":"9","key":"10.1016\/j.jiac.2024.09.005_bib6","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1128\/AAC.41.9.1965","article-title":"Multicenter, randomized study comparing the efficacy and safety of intravenous and\/or oral levofloxacin versus ceftriaxone and\/or cefuroxime axetil in treatment of adults with community-acquired pneumonia","volume":"41","author":"File","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.1016\/j.jiac.2024.09.005_bib7","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.2165\/00003495-200262070-00005","article-title":"Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections","volume":"62","author":"Lamb","year":"2002","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.jiac.2024.09.005_bib14","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/antibiotics10050557","article-title":"Pharmacokinetic\/pharmacodynamic target attainment based on measured versus predicted unbound ceftriaxone concentrations in critically ill patients with pneumonia: an observational cohort study","volume":"10","author":"Gijsen","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jiac.2024.09.005_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1200828","article-title":"Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing","volume":"14","author":"Alasmari","year":"2023","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.jiac.2024.09.005_bib8","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1186\/s12879-019-4552-8","article-title":"1g versus 2 g daily intravenous ceftriaxone in the treatment of community onset pneumonia - a propensity score analysis of data from a Japanese multicenter registry","volume":"19","author":"Hasegawa","year":"2019","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.jiac.2024.09.005_bib16","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/jac\/dkaa067","article-title":"Population pharmacokinetics of ceftriaxone administered as continuous or intermittent infusion in critically ill patients","volume":"75","author":"Leegwater","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jiac.2024.09.005_bib9","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3390\/antibiotics11080983","article-title":"Retrospective comparison of effectiveness and safety of ceftriaxone 1g twice daily versus 2g once daily for treatment of aspiration pneumonia","volume":"11","author":"Kato","year":"2022","journal-title":"Antibiotics"},{"issue":"3","key":"10.1016\/j.jiac.2024.09.005_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061023","article-title":"Optimal duration of antibiotic treatment for community-acquired pneumonia in adults: a systematic review and duration-effect meta-analysis","volume":"13","author":"Furukawa","year":"2023","journal-title":"BMJ Open"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T11:43:39Z","timestamp":1736768619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24002575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S1341321X24002575"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.09.005","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative prospective cohort study of efficacy and safety according to dosage and administration of ceftriaxone for community-acquired pneumonia","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102516"}}